Between The Lines

In this Dermatology Times Between the Lines journal club series, expert panelists discuss the phase 3 STOP-HS trials of povorcitinib, an oral JAK1 inhibitor for moderate-to-severe hidradenitis suppurativa (HS). The discussion covers disease context, trial design, key efficacy and safety findings, and the application of data in real-world practice. The experts emphasize quality of life, pain, and drainage outcomes, as well as the role of advanced systemic therapies in a long-term, individualized treatment journey for HS patients.

Panelists discuss how oral JAK inhibitors are transforming atopic dermatitis management by achieving rapid, sustained control of symptoms across diverse patient populations. They emphasize the importance of individualized care, safety considerations, and aligning treatment goals with patient expectations.

Panelists discuss evidence-based strategies for managing sensitive skin by supporting the skin barrier, highlighting the role of cleansers and moisturizers, the science behind barrier function, and emerging clinical data to guide effective product selection and patient education.

Bruce Strober, MD, PhD, introduces an upcoming series highlighting a clinical trial focused on the efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares.

Raj Chovatiya, MD, PhD, MSCI; and Christopher Bunick, MD, PhD; analyze clinical trial data, compare treatment efficacies of upadacitinib and dupilumab, evaluate quality of life measures, and emphasize the importance of translating study results to real-world atopic dermatitis management strategies.

Lawrence Eichenfield, MD, investigates the efficacy, physician satisfaction, treatment patterns, and outcomes of topical ruxolitinib, a novel therapy for atopic dermatitis, through the review of two recently presented clinical trials.

Expert dermatologists discuss published articles surrounding the efficacy and safety of topical cream treatments on itch relief in adult and pediatric populations with moderate-to-severe atopic dermatitis (AD).

Experts discuss the results of multiple studies analyzing the incident rates and safety of Janus Kinase (JAK) inhibitors in the treatment of atopic dermatitis (AD).

Dermatology experts review and discuss review the practical and clinical implications of the itch and pruritus data from the phase 3 TRuE-AD1 and TRuE-AD2 trials.

Thought leaders share insights on recently published four-year data on the safety and efficacy of dupilumab in adults with moderate-to-severe atopic dermatitis.

Experts in dermatology review an article surrounding generalized pustular psoriasis (GPP) flares and explore the differences in the management and treatment of patients with GPP experiencing disease flares vs those without.

Expert dermatologists review the role of non-prescription moisturizers and cleansers in the treatment of acne.